Creative Medical Technology (CELZ) said Friday that it received a notice of allowance from the US Patent and Trademark Office for ImmCelz for the treatment of heart failure and post-infarct pathological remodeling.
Once granted, the patent will be in effect until at least 2040, the biotechnology company said.
The patent has broad claims on using ImmCelz via a minimally invasive outpatient procedure to treat patients at risk of developing or who already have heart failure, the company said.
Shares of the company were up 4.5% in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。